The skin: an immunoreactive target organ during interleukin-2 administration?

Dermatologica. 1991;183(2):95-9. doi: 10.1159/000247645.

Abstract

Six patients with metastatic malignant melanoma were treated systemically with dacarbazine and interleukin-2 (IL-2). During IL-2 administration all patients developed a macular erythematous rash followed by scaling which began 24-48 h after IL-2 infusion. The dermatological changes were associated with elevated interferon-gamma and tumor necrosis factor alpha serum levels (immunoradiometric assay). Histology revealed nonspecific spongiotic foci in the epidermis and a perivascular mononuclear infiltrate in the dermis. Immunohistochemistry characterized this infiltrate mainly as activated T helper lymphocytes and revealed the expression of intercellular adhesion molecule 1 by endothelial cells and keratinocytes that might have been induced by interferon-gamma. The skin reactions associated with systemic IL-2 administration, show that the skin actually participates as a target organ. They should be differentiated from drug eruptions.

Publication types

  • Clinical Trial

MeSH terms

  • Biopsy
  • Combined Modality Therapy
  • Cytokines / blood
  • Dacarbazine / administration & dosage
  • Dacarbazine / therapeutic use*
  • Dermatitis / blood
  • Dermatitis / etiology*
  • Dermatitis / pathology
  • Humans
  • Immunohistochemistry
  • Immunoradiometric Assay
  • Interferon-gamma / blood
  • Interleukin-2 / administration & dosage
  • Interleukin-2 / adverse effects*
  • Melanoma / therapy*
  • Skin Neoplasms / therapy*
  • T-Lymphocyte Subsets / pathology
  • Tumor Necrosis Factor-alpha / analysis

Substances

  • Cytokines
  • Interleukin-2
  • Tumor Necrosis Factor-alpha
  • Dacarbazine
  • Interferon-gamma